MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
9.80
+0.01
+0.10%
After Hours: 9.76 -0.04 -0.41% 16:05 07/12 EDT
OPEN
9.90
PREV CLOSE
9.79
HIGH
10.24
LOW
9.71
VOLUME
1.52M
TURNOVER
0
52 WEEK HIGH
17.57
52 WEEK LOW
5.12
MARKET CAP
746.06M
P/E (TTM)
-4.6800
1D
5D
1M
3M
1Y
5Y
1D
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
NASDAQ · 4d ago
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Shares of NVIDIA Corporation rose during Tuesday's session. The Dow Jones index fell around 100 points on Tuesday. Kymera Therapeutics, Inc. Shares rose 21.7% to $38.91 and Jumia Technologies AG shares surged 20.7%. Other big stocks recording gains include Micron Technology, Cirrus Logic and Newegg.
Benzinga · 5d ago
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Barchart · 6d ago
Weekly Report: what happened at TVTX last week (0701-0705)?
Weekly Report · 6d ago
Weekly Report: what happened at TVTX last week (0624-0628)?
Weekly Report · 07/01 11:58
Weekly Report: what happened at TVTX last week (0617-0621)?
Weekly Report · 06/24 12:08
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
NASDAQ · 06/24 11:32
Weekly Report: what happened at TVTX last week (0610-0614)?
Weekly Report · 06/17 11:56
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.